Aarti Pharmalabs · NSE: AARTIPHARM · BSE: 543748
Q4 FY23 results · Jan–Mar 2023
Aarti Pharmalabs reported revenue from operations of ₹485.06 crore and net profit of ₹42.87 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 485.06 | — | — | — | — |
| Other income | 0.74 | — | — | — | — |
| Total income | 485.80 | — | — | — | — |
| Profit before tax | 58.84 | — | — | — | — |
| Net profit for the period | 42.87 | — | — | — | — |
| EPS, basic (₹) | 4.73 | — | — | — | — |
| Net margin (%) | 8.8 | — | — |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 374.27 | — | — | — | — |
| Other income | 0.00 | — | — | — | — |
| Total income | 374.27 | — | — | — | — |
| Profit before tax | 56.74 | — | — | — | — |
| Net profit for the period | 39.99 | — | — | — | — |
| EPS, basic (₹) | 4.41 | — | — | — | — |
| Net margin (%) | 10.7 | — | — |
Consolidated
- Filed with BSE
- 18 May 2023, 15:35 IST
- Board meeting
- 12 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2023, 15:35 IST
- Board meeting
- 12 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE